Plain-English translation of NCT07813572 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is comparing two different drug combinations to treat advanced hepatocellular carcinoma (liver cancer). You would receive either ZG005 plus , or plus —both given as intravenous infusions every three weeks. Researchers want to see which combination works better for patients who are being treated for this condition for the first time.
Currently, doctors use combined with to treat advanced liver cancer. This trial is testing whether ZG005—a newer medication—combined with might be even more effective, offering patients a potentially better treatment option.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to receive one of the two drug combinations. Every three weeks, you will come to the clinic for an intravenous infusion of your assigned medications. The study team will monitor you regularly with blood tests and imaging scans to track how well the treatment is working and watch for any side effects. Your exact treatment duration will depend on how you respond and how well you tolerate the medication.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Enrollment target
~600 participants
Started
October 2026
Primary completion
September 2031
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wei Chen
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.